{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/influenza-seasonal/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"ecde5124-7df2-5d70-921e-cfa13a752476","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 2677afa3-6849-44e9-b345-ae81bb3a9fb4 --><h2>Changes</h2><!-- end field 2677afa3-6849-44e9-b345-ae81bb3a9fb4 -->","summary":null,"htmlStringContent":"<!-- begin item 257fdee3-1474-402d-9367-856ff01a4309 --><!-- begin field baa47625-7cc7-48e7-ba02-37584cf09970 --><p><strong>August 2020</strong> — minor update. Broken URL link updated.</p><p><strong>April 2019</strong> — reviewed. A literature search was conducted in April 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. </p><!-- end field baa47625-7cc7-48e7-ba02-37584cf09970 --><!-- end item 257fdee3-1474-402d-9367-856ff01a4309 -->","topic":{"id":"7143131b-dc98-5d14-aef2-f50114a27d13","topicId":"c00149e5-18ab-49c6-8576-089384091df2","topicName":"Influenza - seasonal","slug":"influenza-seasonal","lastRevised":"Last revised in August 2020","chapters":[{"id":"415ca83c-583b-5dd7-8ce7-a67a72325836","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"39d27467-6801-59da-a28b-29a9a1aa848d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7326279e-c8e9-5783-9cb0-433a2e0c5061","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ecde5124-7df2-5d70-921e-cfa13a752476","slug":"changes","fullItemName":"Changes"},{"id":"b4d67dc6-a391-5644-a3a4-89c1c0c49e3f","slug":"update","fullItemName":"Update"}]},{"id":"3b2a94ae-a366-5ff9-8a35-6f8eb63736a1","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8b66965c-fc03-5267-ac06-f0edc2bf81ea","slug":"goals","fullItemName":"Goals"},{"id":"32bc1d45-c0ea-55ed-8723-fdbf13b7196e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c5aa9558-010a-5b32-b95a-40f647ef373e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b9c5c598-f72e-505f-b951-cbe710a6af02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d0c6ad8d-5845-5dfd-b2d0-b04bb5395c62","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"48e0bfcd-fd33-552c-b052-28533a176218","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"feb6e56c-e4f6-57f4-bbee-0876089197e0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bc17d7e2-a53a-595c-9f57-7080c9814001","slug":"definition","fullItemName":"Definition"},{"id":"d0475ee5-11e2-5ad5-8628-4f513e50236f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0aabed4-a912-518e-9257-8653bc7541e4","slug":"complications","fullItemName":"Complications"}]},{"id":"f81fdd28-028a-5558-92b2-90a1569692bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dcd79bc4-67e6-52b5-af13-ab18772e4c55","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4da6c7b5-c872-551a-aff9-100bef3041ca","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b540d9e5-48f5-5b1c-a8b1-8a37d951449f","fullItemName":"Management","slug":"management","subChapters":[{"id":"9cbc6ee5-b0da-5b46-9ce4-3704f7cf24a9","slug":"treating-influenza","fullItemName":"Scenario: Treating influenza"},{"id":"b82606d4-79c4-5b96-84cd-115c371c80b4","slug":"post-exposure-prophylaxis","fullItemName":"Scenario: Post-exposure prophylaxis"}]},{"id":"267c67be-5fb6-510f-b3f7-15ece61003d9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"418c695e-c703-5e30-9ec2-9bf2afeb6001","slug":"oseltamivir","fullItemName":"Oseltamivir"},{"id":"370b7394-2bad-5d4f-ac2a-06de67bbefea","slug":"zanamivir","fullItemName":"Zanamivir"}]},{"id":"83f51ef5-d6f9-5101-849d-c72bd5975126","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fe85159c-da36-5171-9b52-88d8edd9ee77","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"46f280be-d769-501b-905f-789bbf2d8454","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9904923d-c7de-53aa-8253-15c9392ece2e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3790de44-d79a-5486-b053-d09c6dccc2cc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7e631b66-3030-5dd0-97e7-7504198b5a14","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ab624014-37fa-5613-976c-e2ffa65a7e90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b4d3fc-b6de-5df4-ad98-bf9ea439e342","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7326279e-c8e9-5783-9cb0-433a2e0c5061","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"a4f0d8b3-79f5-532d-a642-aedbaf9e612a","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 937e41f2-0aec-400d-8a52-2a9010f30ea9 --><h3>Previous changes</h3><!-- end field 937e41f2-0aec-400d-8a52-2a9010f30ea9 -->","summary":null,"htmlStringContent":"<!-- begin item 97c82928-74c7-4a46-9459-d7934e1e58aa --><!-- begin field 95d9e9ff-913f-4e34-a126-bb49c98d28f4 --><p><strong>October 2015 </strong>— minor update. Following an update to the Summary of Product Characteristics for Tamiflu<sup>® </sup>(oseltamivir), the topic has been updated to reflect that oseltamivir is now licensed for:</p><ul><li>The treatment of influenza in adults and children (including full-term neonates) who present with symptoms typical of influenza, when influenza virus is circulating in the community.</li><li>The post-exposure prophylaxis of influenza in:<ul><li>Adults and children aged 1 year and over following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.</li><li>Infants younger than 1 year of age during a pandemic influenza outbreak.</li></ul></li></ul><p><strong>December 2014 </strong>— minor update. Topic was checked to ensure that it is in line with the recently published Public Health England (PHE) guideline <em>The treatment and prophylaxis of influenza</em>, the recommendations have not changed but some minor text changes have been made.</p><p><strong>October 2013 </strong>— reviewed. A literature search was conducted in September 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. The following revisions have been made in line with recommendations from the Health Protection Agency(HPA) <em>HPA guidance on use of antiviral agents for the treatment and prophylaxis of influenza</em> and the UK Teratology Information Service (UKTIS) <em>Use of oseltamivir in pregnancy</em>:</p><ul><li>Oseltamivir is now recommended to be prescribed to otherwise healthy people if the prescriber feels that the person is at risk of developing serious complications from influenza.</li><li>People considered to be 'at risk' from influenza has been revised to include women up to two weeks post partum and people with morbid obesity (body mass index of 40 or more).</li><li>Oseltamivir is now recommended over zanamivir for the treatment of pregnant women exposed to the influenza virus, except in cases of known or suspected oseltamivir resistance.</li></ul><p>The scope of the topic had been reduced to cover only seasonal influenza.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>November 2011 </strong>— minor update. The doses of oseltamivir in renal impairment have been updated in line with the British National Formulary (BNF). Issued in December 2011.</p><p><strong>September 2011 </strong>— minor update. The references have been revised to include updated guidance from the Department of Health's <em>Immunisation against infectious disease — the 'Green Book' </em>chapter 19, Influenza (updated in July 2011). Issued in October 2011.</p><p><strong>July 2011 </strong>— minor update. More exact paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency. Prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>February 2011 </strong>— minor update. Recent advice from the Chief Medical Officer regarding prescribing antivirals to people who are <em>not </em>in clinical risk groups has been added. Issued in February 2011.</p><p><strong>November 2010 </strong>— minor update. Part XVIIIB of the <em>Drug tariff</em>, which defines the circumstances in which oseltamivir and zanamivir may be prescribed, has been updated. Issued in November 2010.</p><p><strong>September 2010 </strong>— minor update. Text has been added to remind prescribers that antiviral drugs should only be prescribed when national surveillance schemes indicate that influenza is circulating in the community. Issued in September 2010.</p><p><strong>July 2010 </strong>— minor update. Zanamivir and oseltamivir are no longer 'black triangle' drugs. Prescriptions updated. Issued in July 2010.</p><p><strong>February 2010 </strong>— minor update. A recent <em>Drug safety update </em>from the Medicines and Healthcare products Regulatory Agency (MHRA) indicates that there remains no evidence to suggest that zanamivir and oseltamivir carry any risks to pregnancy. Issued in February 2010.</p><p><strong>March to August 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The scope of the topic had been reduced to cover only seasonal influenza. Information on avian influenza will be covered in a subsequent CKS topic.</p><p><strong>June 2009 </strong>— minor update. Additional swine flu link added. Issued in June 2009.</p><p><strong>May 2009 </strong>— minor update. Links to information sources regarding 'swine flu' have been added to <em>Have I got the right topic? </em>and <em>Which scenario? </em>Issued in June 2009.</p><p><strong>October 2008 </strong>— minor update. Updated to include a review of NICE technology appraisal guidance 67 previously issued in September 2003, evaluating the use of oseltamivir, amantadine, and zanamivir for the prophylaxis of influenza. Issued in November 2008.</p><p><strong>August 2008 </strong>— minor update. Updated reference added for the WHO pandemic alert phase 3: algorithm for the management of returning travellers and visitors from countries affected by avian influenza (H5N1) presenting with febrile respiratory illness: recognition, investigation and initial management. Issued in August 2008.</p><p><strong>May 2007 </strong>— minor update. New safety information from the European Medicines Evaluation Agency (EMEA) on neuropsychiatric adverse effects with oseltamivir added. Issued in May 2007.</p><p><strong>April to June 2006 </strong>— reviewed. Validated in September 2006 and issued in October 2006.</p><p><strong>October 2005 </strong>— updated to include information on how to manage suspected avian influenza and also to incorporate information on two additional groups that the Chief Medical Officer (CMO) now recommends should receive flu immunization. Issued in November 2005.</p><p><strong>July 2005 </strong>— update to prescriptions for oseltamivir. Issued in July 2005.</p><p><strong>April 2005 </strong>— minor update. Oseltamivir and zanamivir may only be prescribed on the NHS in certain circumstances and the prescription must be endorsed 'Selected List Scheme' ('SLS'). Issued in April 2005.</p><p><strong>September 2004 </strong>— updated to include the latest update from the CMO on the influenza immunization programme 2004/2005. Issued in September 2004.</p><p><strong>October 2003 </strong>— updated to incorporate <em>Guidance on the use of oseltamivir and amantadine for the prophylaxis of influenza, </em>technology appraisal guidance no. 67, issued by the National Institute for Health and Care Excellence (NICE) (September 2003); <em>Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza, </em>technology appraisal guidance no. 58, issued by NICE (February 2003); and the influenza immunization programme 2003/2004 issued by the CMO (August 2003). Issued in October 2003.</p><p><strong>September 2002 </strong>— reviewed. Validated in December 2002 and issued in February 2003.</p><p><strong>April 2001 </strong>— updated. Issued in October 2001.</p><p><strong>July 1999 </strong>— written. Validated in October 1999 and issued in January 2000.</p><!-- end field 95d9e9ff-913f-4e34-a126-bb49c98d28f4 --><!-- end item 97c82928-74c7-4a46-9459-d7934e1e58aa -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}